| DIRECT COMPETITOR COMPARISON | |
| IMMU | BIIB | Pvt1 | GSK | Industry | | Market Cap: | 263.91M | 13.72B | N/A | 108.70B | 62.95M | | Employees: | 120 | 4,700 | 11,1741 | 99,003 | 56 | | Qtrly Rev Growth (yoy): | 696.10% | 2.50% | N/A | 14.90% | 21.40% | | Revenue (ttm): | 64.14M | 4.32B | 13.42B1 | 45.11B | 12.73M | | Gross Margin (ttm): | 67.29% | 91.12% | N/A | 76.27% | 50.63% | | EBITDA (ttm): | 38.14M | 1.68B | N/A | 17.78B | -1.76M | | Oper Margins (ttm): | 57.13% | 28.43% | N/A | 34.30% | -19.80% | | Net Income (ttm): | 36.52M | 869.75M | N/A | 8.10B | N/A | | EPS (ttm): | 0.477 | 2.988 | N/A | 3.17 | -0.10 | | P/E (ttm): | 7.36 | 15.88 | N/A | 13.53 | 23.38 | | PEG (5 yr expected): | N/A | 1.38 | N/A | 3.01 | 1.37 | | P/S (ttm): | 4.02 | 3.17 | N/A | 2.37 | 3.30 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.53 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|